Suggested Readings For Diabetes Mellitus

1. Diabetes mellitus: Repot of WHO Study Group, technical report series 727, Geneva, World Health Organisation, 1985.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025.  Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.
3. Simmons D, Williams DR, Powell MJ:  Prevalence of diabetes in different regional and religious South Asian Indian communities in Coventry.  Diabet Med 1992; 9:428-431.
4. Ramachandran A, Snehalatha C, Dharmaraj D, et al:  Prevalence of glucose introlerance in Asian Indians.  Urban-rural difference and significance of upper body adiposity.  Diabetes Care 1992; 15:1348-1355.
5. Report of Expert Committee on Diagnosis and Classification of Diabetes mellitus: Diabetes Care 1997; 20:1183-1197. Karvonen M,Tuomilehto J,Libman I et al  A review of the recent epidemiological data on the incidence of type 1 (insulin-dependent) diabetes mellitus worldwide . Diabetalogia 1993; 36:883-892.
6. Albert KGMM, Zimmet PZ: Definition, diagnosis, and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15:539-553. Efendic S, Luft R, Wajngot A: Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 1984; 5:395-410.  
7. Bajaj M, Purohit A:  Insulin resistance, dyslipidemia and coronary artery disease in type 2 diabetes mellitus – the Indian perspective.  In: Coronary Artery Disease in Indians:  A Global Perspective. Cardiology Society of India.  Ed. Sethi KK. New Delhi: 1999:92-97.
8. Mazze R, Shamoon H, Parmentier R et al: Reliability of glucose monitoring by patients with diabetes. Am J Med 1984; 77:211-217.
9. Tamada JA, Garg S, Jovanovic L et al. Noninvasive glucose monitoring: comprehensive clinical trials. JAMA 1999; 282:1839-1844.
10. The Diabetes Control and Complications Trial Research Group:  The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial.  Diabetes 1995; 44: 968-983.
11. Griffin S. Diabetes care in general practice: Meta-analysis of randomized control trials. BMJ 1998; 317:390-396.
12. ICMR Guidelines for Mangement of Type 2 Diabetes 2004; 19-23.
13. Tuomilehto J, Lindstrom J, Erikkson JG, et al.:  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med 2001; 344:1343-1350.
14. Klein S, Sheard NF, Pi-Sunyer X et al.  Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition.  Diabetes Care 2004; 27:2067-2073.
15. Anderson RJ, Grigsby AB, Freedland KE, et al.  Anxiety and poor glycemic control: a meta-analysis review of the literature.  Int J Psychiatry Med 2002; 32: 235-247.
16. De Fronzo R A. Pharmacologic therapy for Type 2 Diabetes mellitus. Ann Intern Med 1999;131
17. Rosenstock , Samols E, Muchomore et al. Glimepiride , a new once daily sulfonylurea: A  double blind,placebo controlled study of NIDDM patients. Glimepiride study group.  Diabetes care 1996; 19:1194-1199.
18. Owens D R; Repaglinide – Prandial glucose regulator, a new class oral antidiabetc drugs. Diabet Med 1998:15(suppl. 4): S 28
19. Garber AJ, Duncan T G and Goodman A M. Efficacy of metformin in type 2 diabetes; Result of double blind, placebo controlled dose response trial. Am J Med 1997; 103:491-497.
20. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2diabetes mellitus:  systematic review and meta-analysis.  Arch Intern Med 2003 163:2594-2602, 28.
21. Kelly IE. Effects of thiazolidinedione compounds on body fat and fat distribution in patients with Type 2 Diabetes mellitus. Diabetes Care 1999; 22: 288.
22. Lebovitz H E: Alpha glucosidase inhibitors as agents in the treatment of Diabetes  Diabet Rev 1998; 6:132.
23. Holst J J.  Therapy of type 2 diabetes mellitus based on the actions of glucagons-like peptide-1.  Diabetes Metab Res Rev 2002; 18: 430-41.
24. Dewitt D, Hirsch I.  Outpatient insulin therapy in type 1 and type 2 diabetes: scientific review.  F Am Med Assoc 2993; 289: 2254063.
25. Bolli G B, Di Marchi RD, Park G D et al: Insulin analogues and their potential use in the management of Diabetes mellitus. Diabetalogia 1999; 42:1151-1167.
26. Heinemann L, Linkeschova R, Rave K et al: Time-acting profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo: Diabetes Care 2000; 23:644-49.
27. Jacobson L, Sogaard B, Riis A:  Comparison of the pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine retarded insulin as part and a similar premix of human insulin (Abstract). Diabetes 1999; 48 [Suppl 1]: A 108.
28. Alejandro R, Lehmann R, Ricordi C, et al: Long term function of Islet allografts in type 1 diabetes. Diabetes 1997; 46:1983-1989.
29. Ltief A N ,Schwenk W F:Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999; 22:137-140.
30. Selam J L, Micossi P,Dunn F L, et al : Clinical trial of programmable implantable insulin pump for type 1 diabetes. Diabetes Care 1992; 15:877-885.
31. Zinman B, Tildesley H, Chaisson J L, et al: Insulin lispro in CSII: Results of a double blind trial crossover study. Diabetes 1997; 46:440-443.
32. Ovalle G, Bell DSH.  Triple oral anti-diabetic therapy in type 2 Diabetes mellitus. Endocrine Pract. 1998; 4: 146-147.
33. American Diabetes Association Position Statement: Management of dyslipidemia in adults with diabetes. Diabetes Care 2000; 23 (suppl):57-60.
34. Klein R, Klein BEK, Moss SE, et al: Blood pressure and hypertension in diabetes. Am J Epidemiol 1985; 122:75-89.